OncoMethylome Sciences’ technology platform to be used by GSK

Published: 23-Sep-2010
Research & Development Analysis

DNA methylation specific PCR biomarker could be used in immunotherapy development programme


OncoMethylome Sciences, a leading molecular diagnostics company, has entered into an agreement with GlaxoSmithKline Biologicals for the potential use of one of its DNA methylation specific PCR biomarkers in GSKs immunotherapy development programme.

OncoMethylome's biomarker is stable, highly accurate and, unlike many other biomarkers, allows for the analysis of non-invasive tissue samples.

‘We are very pleased to enter into this agreement with GSK. This project was initiated in 2007 and is a prime example of how we can bring our considerable regional strengths to bear on global healthcare issues,’ said Dr Jan Groen, ceor of OncoMethylome.

‘Furthermore, this agreement marks an important step for our company in the use of our biomarker with certain immunotherapeutics in development by GSK, and underpins our strategy of leveraging our methyla-tion specific PCR platform in the rapidly emerging field of companion diagnostics and personalised medicine.’

  • Companies:
  • OncoMethylome Sciences SA
See more

You may also like

Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

Read more
The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c

Trending Articles

  1. Isospec Analytics launches biomolecular analysis technology to identify unknown molecules The novel technology optimises the identification process of unknown molecules compared to mass analysis
  2. ACG awarded ‘Great Place To Work’ certification for a fourth consecutive year The award recognises employers that create an outstanding experience for employees
  3. IMPACT CKD model reveals the escalating toll of chronic kidney disease The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
  4. Edward Rayner appointed as as Non-Executive Director of Sphere Fluidics Ed’s appointment will strengthen the company’s strategic vision as it progresses ambitious plans for future growth and commercial success
  5. Beckman introduces novel CE-Marked Hepatitis Assays at ESCMID Global The HBsAg high positive algorithm eliminates the need for repeat and confirmatory testing for samples ≥ 100.00 S/CO

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Manufacturing

Ardena's nanomedicines facility marks expansion with first GMP approval

The EUR €20m expansion to the nanomedicines facility at Pivot Park has achieved operational status by the Dutch Healthcare Authority
Research & Development

Compact process thermostat for efficient temperature control in the laboratory

The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
Analysis

Beckman introduces novel CE-Marked Hepatitis Assays at ESCMID Global

The HBsAg high positive algorithm eliminates the need for repeat and confirmatory testing for samples ≥ 100.00 S/CO
Manufacturing

ACG awarded ‘Great Place To Work’ certification for a fourth consecutive year

The award recognises employers that create an outstanding experience for employees
Analysis

Titan Enterprises’ 800-series turbine flow meters provide a low-cost solution for the pharmaceutical industry

Titan's flowmeters can assist in accurate batch delivery and dispensing systems for low viscosity liquids for incorporation in ingestible pharmaceutical products
Regulatory

Isospec Analytics launches biomolecular analysis technology to identify unknown molecules

The novel technology optimises the identification process of unknown molecules compared to mass analysis
Subscribe now